global Glycosylated hemoglobin and C-peptide market was valued at $2,945.0 million in 2025 and is projected to reach $6,240.2 million by 2035, growing at a CAGR of 7.9% during the forecast period (2026-2035. The growing global diabetes burden continues to expand the population requiring routine glycemic assessment and long-term metabolic monitoring, directly supporting demand for HbA1c and C-peptide testing. According to the International Diabetes Federation (IDF) Diabetes 11.1% of the global adult population, or 1 in 9 adults aged 20–79, is currently living with diabetes, with more than 40% remaining undiagnosed. In absolute terms, around 589 million adults were living with diabetes globally in 2024, indicating the scale of unmet diagnostic and monitoring needs across healthcare systems.
Browse the full report description of “Global Glycosylated Hemoglobin And C Peptide Market Size, Share & Trends Analysis Report By Product (Tablet, Capsules, Injectable, and Others), By Application (Oncology, Blood Disorder, Diabetes, and Other) Forecast 2026-2035” at https://www.omrglobal.com/industry-reports/glycosylated-hemoglobin-and-c-peptide-market
Projections indicate that diabetes prevalence will continue to rise materially over the coming decades, with the IDF estimating that the number of adults living with diabetes will reach approximately 853 million by 2050, representing a 46% increase from current levels. More than 90% of cases are type 2 diabetes, driven by structural factors such as urbanization, aging populations, declining physical activity, and rising obesity rates. This expanding and increasingly monitored population reinforces recurring utilization of HbA1c testing for glycemic control assessment and supports growing use of C-peptide assays to guide diagnosis and treatment decisions, particularly in settings focused on early detection, disease classification, and complication prevention.
Key Leaders Transforming the Glycosylated Hemoglobin and C-Peptide Market
The key players in the glycosylated hemoglobin and c-peptide market include Abbott Labs, Roche Diagnostics, Siemens Healthineers, Danaher Corp., Bio-Rad Labs, among others. These companies are driving innovation in glycosylated hemoglobin and C-peptide testing through the development of high-precision assay technologies, improved analytical sensitivity and turnaround times, and expanded point-of-care and laboratory automation capabilities, supporting more accurate diabetes diagnosis, monitoring, and treatment decision-making across global healthcare markets.
Market Coverage
Key questions addressed by the report.
Global Glycosylated Hemoglobin and C-Peptide Market Report Segment
By Type
By Test Type
By End-Users
Global Glycosylated Hemoglobin and C-Peptide Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/glycosylated-hemoglobin-and-c-peptide-market